Participant flow

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus · Source last updated 2016-11-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV

   id

   FG000

   title

   Treatment (Temsirolimus)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Disease Progression

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      alternative therapy

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         8

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

A total of 8 patients were enrolled at two institutions between July 2010 and January 2012

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice